2022      |      2021      |      2020      |      2019      |      2018
Key events in 2018

 

Date Event Title Add to Calendar
21 Dec (i) Licence agreement; and (ii) manufacturing and supply agreement entered into with Orient EuroPharma Co. Ltd. for the commercial launch of Fortacin™ in select territories in Asia, ex The People's Republic of China N/A
03 Dec (i) Licence agreement; and (ii) manufacturing and supply agreement entered into with Wanbang Pharmaceutical Marketing and Distribution Co., Ltd. for the commercial launch of Fortacin™ in The People's Republic of China N/A
19 Oct Successful registration of Fortacin™ in Hong Kong with the Hong Kong Department of Health - Drug Office N/A
24 Aug 2018 Interim Results Announcement N/A
06 Jul Official registration of the Phase II validation study of Fortacin™ in respect of the Food and Drug Administration approval process in the United States N/A
14 Jun 2018 Annual General Meeting
19 Apr Successful registration of Fortacin™ in Macau with the Macau Government - Health Bureau N/A
23 Mar Receipt of a total of €4 million from Recordati during the period from 5 March 2018 to 23 March 2018 following the first commercial sale of Fortacin™ on schedule in each of Italy, France, Spain, Germany and Portugal N/A
23 Mar 2017 Annual Results Announcement N/A
09 Feb Official launch, by way of first commercial sales from Recordati, to wholesalers in Italy, with first Fortacin™ sales expected to follow in France and Spain on 16 and 19 February 2018, respectively, and thereafter in Germany and Portugal on 1 March 2018 N/A